Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC

被引：0
|
作者：
Borghaei, H. [1 ]
Langer, C. J. [2 ]
Gadgeel, S. [3 ]
Papadimitrakopoulou, V. A. [4 ]
Patnaik, A. [5 ]
Powell, S. F. [6 ]
Gentzler, R. D. [7 ]
Martins, R. G. [8 ]
Stevenson, J. P. [9 ]
Jalal, S. I. [10 ]
Panwalkar, A. [11 ]
Yang, J. C-H. [12 ]
Gubens, M. [13 ]
Sequist, L. [14 ]
Awad, M. M. [15 ]
Fiore, J. [16 ]
Saraf, S. [16 ]
Raftopoulos, H. [16 ]
Gandhi, L. [17 ]
机构：
[1] Fox Chase Canc Ctr, Hematol & Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[2] Abramson Canc Ctr, Dept Med, Philadelphia, PA USA
[3] Karmanos Canc Inst, Thorac Oncol, Detroit, MI USA
[4] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Oncol, Houston, TX 77030 USA
[5] South Texas Accelerated Res Therapeut, Clin Res, San Antonio, TX USA
[6] Sanford Heath, Oncol, Sioux Falls, SD USA
[7] Univ Virginia, Hematol Oncol, Charlottesville, VA USA
[8] Univ Washington, Med, Seattle, WA 98195 USA
[9] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[10] Indiana Univ Sch Med, Internal Med, Indianapolis, IN 46202 USA
[11] Sanford Roger Maris Canc Ctr, Hematol Oncol, Fargo, ND USA
[12] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[13] Univ Calif San Francisco, Med Oncol, San Francisco, CA 94143 USA
[14] Massachusetts Gen Hosp, Hematol Oncol, Boston, MA 02114 USA
[15] Dana Farber Canc Inst, Thorac Oncol, Boston, MA 02115 USA
[16] Merck & Co Inc, Clin Res, Kenilworth, NJ USA
[17] NYU Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA49
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799.
    Jabbour, Salma K.
    Lee, Ki Hyeong
    Frost, Nicolaj
    Kowalski, Dariusz
    Breder, Valeriy Vladimirovich
    Pollock, Theodore
    Reguart, Noemi
    Houghton, Baerin
    Quantin, Xavier
    Keller, Steven M.
    Liu, Hong
    Piperdi, Bilal
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study
    Antonia, Scott Joseph
    Brahmer, Julie R.
    Balmanoukian, Ani Sarkis
    Kim, Dong-Wan
    Kim, Sang-We
    Ahn, Myung-Ju
    Jamal, Rahima
    Jaeger, Dirk
    Ott, Patrick Alexander
    Ascierto, Paolo Antonio
    Gregorc, Vanesa
    Goldman, Jonathan Wade
    Blakely, Collin M.
    Jin, Xiaoping
    Antal, Joyce
    Gupta, Ashok Kumar
    Segal, Neil Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.
    Gadgeel, Shirish M.
    Garassino, Marina Chiara
    Esteban, Emilio
    Speranza, Giovanna
    Felip, Enriqueta
    Hochmair, Maximilian J.
    Powell, Steven Francis
    Cheng, Susanna Y.
    Bischoff, Helge
    Peled, Nir
    Hui, Rina
    Reck, Martin
    Kurata, Takayasu
    Garon, Edward B.
    Boyer, Michael J.
    Yang, Jing
    Pietanza, Maria Catherine
    Rodriguez-Abreu, Delvys
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] A RANDOMIZED PHASE 3 TRIAL COMPARING PEMETREXED/CARBOPLATIN (PC) AND DOCETAXEL/CARBOPLATIN (DC) AS FIRST-LINE TREATMENT FOR ADVANCED, NON-SQUAMOUSNON-SMALL CELL LUNG CANCER (NSCLC)
    Ganju, V
    Pereira, J. R.
    Kim, J. H.
    Lee, D. H.
    Wang, J.
    Barraclough, H.
    Holt, S.
    van Kooten, M.
    Orlando, M.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S167 - S168
  • [25] Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
    Rha, S. Y.
    Wyrwicz, L. S.
    Weber, P. E. Y.
    Bai, Y.
    Ryu, M. H.
    Lee, J.
    Rivera, F.
    Alves, G. V.
    Garrido, M.
    Shiu, K. -k.
    Fernandez, M. Gonzalez
    Li, J.
    Lowery, M.
    Cil, T.
    Cruz, F. J. S. M.
    Qin, S.
    Yin, L.
    Bordia, S.
    Bhagia, P.
    Oh, D-y.
    ANNALS OF ONCOLOGY, 2023, 34 (03) : 319 - 320
  • [26] 65 plus: A randomized phase III trial of pemetrexed and bevacizumab versus pemetrexed, bevacizumab, and carboplatin as first-line treatment for elderly patients with advanced nonsquamous, non-small cell lung cancer (NSCLC).
    Schuette, Wolfgang
    Nagel, Sylke
    Schneider, Claus-Peter
    Engel-Riedel, Walburga
    Schumann, Christian
    Kohlhaeufl, Martin
    Serke, Monika
    Hoeffken, Gert
    Kortsik, Cornelius
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)
    Vuky, Jacqueline
    Balar, Arjun Vasant
    Castellano, Daniel E.
    O'Donnell, Peter H.
    Grivas, Petros
    Bellmunt, Joaquim
    Powles, Thomas
    Bajorin, Dean F.
    Hahn, Noah M.
    De Wit, Ronald
    Savage, Mary
    Pang, Lei
    Frenkl, Tara L.
    Keefe, Stephen Michael
    Plimack, Elizabeth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] Carboplatin-paclitaxel/nab-paclitaxel with or without pembrolizumab in first-line metastatic squamous NSCLC: Results from the KEYNOTE-407 east Asia subgroup
    Kato, T.
    Lee, S.
    Cheng, Y.
    Lee, G-W.
    Lee, K.
    Luft, A.
    Trigo, J.
    Hui, R.
    Balint, B.
    Robinson, A.
    Okamoto, I.
    Gerstner, G. J.
    Paz-Ares, L.
    Li, X.
    Shentu, Y.
    Piperdi, B.
    Tafreshi, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 151 - 151
  • [29] Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.
    McDermott, David F.
    Lee, Jae-Lyun
    Szczylik, Cezary
    Donskov, Frede
    Malik, Jahangeer
    Alekseev, Boris Yakovlevich
    Larkin, James M. G.
    Matveev, Vsevolod Borisovich
    Gafanov, Rustem Airatovich
    Tomczak, Piotr
    Tykodi, Scott S.
    Geertsen, Poul F.
    Wiechno, Pawel J.
    Shin, Sang Joon
    Pouliot, Frederic
    Gordoa, Teresa Alonso
    Li, Wenting
    Perini, Rodolfo F.
    Schloss, Charles
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Randomized phase III study of first-line pembrolizumab plus pemetrexed/platinum followed by pembrolizumab and maintenance olaparib versus pemetrexed in patients with metastatic nonsquamous non-small cell lung cancer (NSCLC): KEYLYNK-006.
    Gray, Jhanelle Elaine
    Owonikoko, Taofeek Kunle
    Kato, Terufumi
    Zorrilla, Andres Felipe Cardona
    Wagman, Joanne
    Chen, Xinqun
    Zhao, Bin
    Schulz, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345